Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Agios Pharmaceuticals announces U.S. FDA grants fast track designation to AG-221 for treatment of patients with Acute Myelogenous Leukemia That Harbor an IDH2 Mutation


Wednesday, 13 Aug 2014 08:30am EDT 

Agios Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation.AG-221 is first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in Phase 1 clinical trial in patients with advanced hematologic malignancies. 

Company Quote

96.6
4.93 +5.38%
27 Mar 2015